Thorsten Lewalter - LAA Occlusion therapy: Where do we go from here?

Posted on 13-03-15

About this lecture

Future perspectives for LAAO. What is the impact of the US market (FDA approval) on the rest of the world. New players, new devices are they going to change the outlook? What is the role of the scientific community to drive the adoption of the therapy? And the industry? Implanters, referrers (Neuro, GI, nephrologists etc).

Subjects related to this video

Clinical Evidence Indications & Referral LAAO Implantation

Related video's

David Hildick Smith - What’s new: clinical data published and presented since last year

New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Clinical Evidence Scientific Meetings

Matthew Price - What’s new: cost effectiveness and health economics

Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
Clinical Evidence Scientific Meetings

David Meerkin - What’s new: new devices and new technologies

Review of new left atrial appendage occlusion devices that came to market (CE-mark) or underwent a major redesign in 2016.
LAAO Implantation
To lecture overview